1975  **Baxa Corporation** is founded in Northbrook, Illinois, by Brian Baldwin and Ron Baxa as the first company to market pre-packaged inhalation drugs in pre-filled syringes. Unique **Exacta-Med® Oral Liquid Dispenser** provides accurate and safe delivery of oral liquid drugs.

1977  Baxa transfers sales of pre-packaged inhalation drugs to private-label customer, which later discontinues the product line. Marketing shifts to a focus on **unit dose preparation** through sales of empty Exacta-Med Oral Liquid Dispensers and related products, which grow steadily.

1979  Baxa Corporation is sold to **Cook Group** of Indiana.

1981  **Baxa relocates to Denver, Colorado** to join sister Cook company, Western Research Laboratories.

1986  The company moves to its own facility in an industrial park in the south-central suburbs of Denver.

1987  Four partners, including Brian Baldwin, lead a leveraged buyout of Baxa Corporation from Cook.

1988  Brian Baldwin invents the **Exacta-Med Pharmacy Pump**. This peristaltic pump, the first designed exclusively for pharmacy use, was subsequently awarded a US patent (1991).

**Baxa UK** established as a Baxa distributor in Bracknell, England.

1989  A prototype compounder for TPN (total parenteral nutrition), the **MicroMacro™ Compounder**, is developed from the company's core technologies and introduced at the American Society of Health-System Pharmacists (ASHP) Mid-Year Clinical Meeting. Response is overwhelming, and prompts the creation of operating and calculation software.

Baxa expands into a 46,000 square foot facility in **Englewood, Colorado** to accommodate the rapidly growing business.

The first **GoodNews newsletter** is mailed.

Baxa Operations installs a Multi-Vac custom product packaging system.

1990  UK operations acquired as a wholly owned subsidiary.

1991  **First MicroMacro TPN Compounder install** in the United States – Harris Methodist. Baxa acquires Apothecary Software's TPN-PC™ and TPN-PC™ Plus software packages to automate TPN calculation, admixture verification, label preparation, and patient record management. The software is integrated with the TPN hardware to create a complete TPN compounding system.

1992  Second-generation pharmacy pump, the **Repeater™ Pump**, is introduced, an evolution from the unique Exacta-Med Pump design.

1993  Baxa produces its first four-color product catalog.

1994  100th MicroMacro Compounder is installed worldwide.

Outbound Telesales Center begins operation.

1995  **Baxa celebrates 20 years of innovation** in products for health-system pharmacies.

2,000th Repeater Pump is sold worldwide.

**Exacta-Mix™ Universal Pump** is introduced.

**The Dual Rate Syringe Infuser** (DRI) is introduced for intermittent, fixed-rate drug delivery.

Employment grows to 150 employees, worldwide.

1996  Baxa introduces a high-quality line of sterile filtration products for pharmacy admixture, in a joint-venture with **Gelman Sciences**.

Baxa and **Abbott Laboratories** enter into a long-term cooperative marketing and development plan for TPN compounding products.
Florida Hospital system implements Dual Rate Infuser system.

1997
Certification to the quality standards for ISO 9001 through Orion (ORI). The achievement is a milestone in company efforts to meet the highest level of design and production capability in the industry.

1998
Baxa introduces the MicroFuse® Infuser. This second-generation syringe infuser features enhanced durability and superior performance which allows Baxa to be the “partner of choice” for implementing small-volume syringe infusion systems.

Baxa achieves certification to EN46001, the standards for CE conformance for medical devices in the European Community.

New tip design for Exacta-Med Oral Dispensers eliminates the potential for inadvertent IV administration of oral medications. Tip design will not accommodate a hypodermic needle or actuate a needleless valve.

Baxa signs co-marketing agreement with Abbott Laboratories for the MicroFuse Infuser. The agreement allows Abbott to fill a gap in their portfolio of electronic drug delivery devices.

1999
New Repeater Pump introduced for pharmacy fluid transfer. Design enhancements make the pump more reliable, convenient and durable.

2000
Baxa celebrates its 25-Year Anniversary, emphasizing its focus on service and innovation at the ASHP Mid-Year exhibit in Las Vegas, Nevada.

Baxa UK expands its facilities to separate office, administration and warehousing activities.

2001
The Exacta-Mix 600 Universal Pump is enhanced with the release of 32-Bit Direct-Entry™ Software featuring user-friendly graphics and menus.

Next-generation TPN-PC and PC Plus Software is released, incorporating user-directed changes for enhancing safety and efficiency for TPN compounding and calculation.

CALC™ Software is released, providing a calculation foundation for health management system software packages.

Baxa introduces new logo and tagline. Technology for Solutions reinforces the company's position as the industry leader for fluid handling technology and creating true solutions for pharmacy needs.

2002
The Exacta-Mix 2400 Compounder is introduced, offering state-of-the-art technology for multi-source solution compounding. The EM2400 System is the market leader for pharmacy efficiency and innovation.

2003
The Rapid-Fill™ Automated Syringe Filler is introduced, the first system designed to automate sterile batch filling in the pharmacy. Automating the process of filling, capping and labeling sterile syringes minimizes the potential for contamination and reduces pharmacy overhead.

Abacus – Windows®-based order entry and calculation software for TPN compounding introduced.

Baxa signs agreement with Carmel Pharma ab to become the exclusive US distributor of the PhaSeal® products, a closed system for safe handling of hazardous drugs.

Baxa opens new 93,000 ft² headquarters facility in suburban Denver, with an 8,000 ft² ISO Class V cleanroom.

Baxa UK launches a full line of enteral syringes with connectors that directly fit feeding lines. The syringes' distinctive purple plunger fits the color coding for enteral products in Europe.

2004
Baxa UK releases the CyTwo-Fer™ Needle for vented reconstitution of hazardous drugs.

Baxa expands its corporate headquarters, opening a new 15,000 ft² building housing the sales and marketing functions.

2005
Baxa has its first $8 million sales month.

Brian Baldwin named Ernst & Young 2005 Entrepreneur of the Year.

Baxa moves to direct sales in Canada, Benelux, Finland and France.

Achieved compliance to European Waste Electrical and Electronics Equipment Directive (WEEE).

Agreement signed with Samson Medical Technologies' SmartPak™ Sterile Bulk Bags for prescription compounding.

Baxa earns recognition as: CO Bioscience Top Company of 2005; Governor's Award for Excellence in Exporting; SBA Exporter of the Year and ColoradoBiz Top Company of the Year.
eBUG (electronic Baxa Users’ Group) launched as an online community for information sharing on Baxa
products, pharmacy procedures and current issues.

2006
UK operations expand to new 10,000 ft² facility in Radius Court, Bracknell.

Baxa signs distribution agreement with CDEX Inc. for the ValiMed™ Medication Validation System.

The Skills Training, Academics and Resources Center (STAR) opens for pharmacy best practice, compliance and environmental monitoring training.  The unique facility features negative and positive pressure cleanrooms, classroom and demonstration areas for hands-on and didactic training experiences.

Baxa moves to direct sales in Austria.

Baxa launches the first syringes for the US market designed exclusively for enteral feeding, featuring orange lettering and a distinctive stripe.  Brand name NeoThrive™ designates their focus on neonatal feeding safety.

Baxa named one of the 25 best companies to work for in Colorado by the Society for Human Resource Management.

2007
Baxa and VIASYS MedSystems sign strategic co-marketing agreement for enteral syringes and specialty neonatal feeding sets.

Co-marketing agreement announced with CriticalPoint for its online compliance training software.

Baxa announces direct sales in Switzerland.

Today
Baxa Corporation employs more than 400 associates worldwide, with annual sales of approximately $100 million.

Right-sized product technology differentiates Baxa as a leader in efficiency and safety for fluid medication handling and administration applications.

Focus on the customer – through outstanding customer service and technical assistance, available 24 hours, 7 days a week – set Baxa apart from its competition.

Sales continue to achieve double-digit year-on-year growth levels.  Increased international sales penetration is expected to grow the business exponentially over the next three to five years.

Baxa Corporation is a leading provider of devices and systems for the preparation, handling, packaging, and administration of medications.  The company manufactures and markets a wide range of healthcare products used worldwide in hospital, critical care, and alternate site pharmacies.  Privately held, Baxa Corporation has subsidiaries and sales offices in Canada and the United Kingdom; direct representation in Austria, Belgium, Denmark, Finland, France, Germany, Luxembourg, Switzerland and The Netherlands; and distribution partners worldwide.

# # #

Contact
Marian Robinson
Vice President, Marketing
Baxa Corporation:  800.567.2292 ext. 2157 or 303.617.2157
Email:  marian.robinson@baxa.com